Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HEC73077 · 1 trial · 1 indication
Incidence of adverse events
Maximum plasma concentration of study drugs
area under the concentration versus time curve (AUC) from time zero to infinity
| Arm | Type | Description |
|---|---|---|
| HEC73077 tablets | EXPERIMENTAL | Single-Dose Study: There will be a total of 7 dose cohorts. Multiple-dose Study: There will be a total of 4 dose cohorts. |
| HEC73077 placebo tablets | PLACEBO_COMPARATOR | Single-Dose Study: There will be a total of 7 dose cohorts. Multiple-dose Study: There will be a total of 4 dose cohorts. |
| Name | Type | Description |
|---|---|---|
| HEC73077 tablets | DRUG | Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight. Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study. |
| HEC73077 placebo tablets | DRUG | Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight. Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study. |
Inclusion Criteria: 1. Sign the informed consent form before the trial and fully understand the contents of the trial, the process and possible adverse reactions. 2. Be able to complete the study according to the trail protocol. 3. Subjects (including partners) have no pregnancy plan within 6 month...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| DexCom, Inc. | DXCM | 1 | PHASE3 | Sotagliflozin |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | ALN-ANG3, Evinacumab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | Atrasentan |
| ProKidney Corp. Class A | PROK | 2 | - | Renal Autologous Cell Therapy |
HEC73077 is an investigational small molecule being developed for diabetic nephropathy, a kidney condition that can occur in people with diabetes. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
HEC73077 is being developed by Sunshine Biopharma Inc., a biopharmaceutical company traded on the stock market under the ticker symbol SBFM. The company is conducting clinical research on this investigational drug for diabetic nephropathy.
HEC73077 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not been approved for any use, and further clinical studies would be needed to assess its safety and efficacy.
HEC73077 has one completed Phase 1 clinical trial registered as NCT05492630, titled "Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC73077 in Healthy Subjects." The trial enrolled 138 participants in China and was a randomized, double-blind, placebo-controlled study.
No, HEC73077 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for diabetic nephropathy. The completed Phase 1 trial was conducted in healthy volunteers to evaluate safety, tolerability, pharmacokinetics, and food effects.